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Monoclonal Antibodies for Cancer 
Treatment
Annemeri Livinalli and Taís Freire Galvão
Abstract
Therapeutic monoclonal antibodies have emerged in the 1990 decade as an 
important option for cancer treatment. These molecules have a diverse set of clini-
cally relevant antitumor mechanisms, directly targeting tumor cells. It has been 
established as “standard of care” for several human cancers. This chapter reviews 
the use of monoclonal antibodies in oncology and introduces available biosimilars. 
The requirements for biosimilar antibody development, mechanisms of action and 
current clinical applications for cancer treatment is also presented.
Keywords: biosimilar, equivalence trial, efficacy, monoclonal antibodies, cancer, 
extrapolation of indication
1. Introduction
Since the development of monoclonal antibodies by hybridoma technology in 
1975 [1] over 80 molecules were developed and approved for therapeutic use in 
immunological, oncological, and infectious diseases [2]. Over time, these molecules 
have revolutionized the treatment of main autoimmune diseases and cancer that 
previously had a bleak prognosis. These molecules are usually administered by 
subcutaneous or intramuscular routes due to poor oral bioavailability (less than 1%) 
caused by large size, polarity, limited membrane permeability, and poor gastroin-
testinal stability [3].
In oncology, the approach in the use of monoclonal antibodies consists in 
targeting tumor antigens and killing cancer cells [4]. Growth factor receptors that 
are overexpressed in tumor cells are recognized as main target by monoclonal 
antibodies [4, 5]. Blocking ligand binding/signaling result in decrease growth rate 
of cancer cells, which in turn, induce apoptosis and sensitize tumors cells to chemo-
therapy [6, 7].
As of the first semester of 2021, the arsenal of monoclonal antibodies in oncol-
ogy counts on more than 30 molecules [8]. Among the first molecules, we have: 
bevacizumab, cetuximab, rituximab, trastuzumab, indicated for treating solid 
tumors and hematological malignancies (Table 1). From all monoclonal antibod-




Monoclonal antibody European of Medicines Agencya Food and Drug Administrationb
Trade name Approval date Trade name Approval date
Bevacizumab Mvasi 2018 Mvasi 2017






Rituximab Truxima 2017 Truxima 2018
Riximyo 2017 Ruxience 2019






Approval date Mechanism of action Indication in oncology
EMAa FDAb
Bevacizumab 2005 2004 Inhibition of vascular 
endothelial growth factor 
binding to the cell surface 
receptors
Metastatic colorectal cancer; 
unresectable, locally advanced, 
recurrent, or metastatic non-
squamous non-small cell lung 
cancer; recurrent glioblastoma 
in adults; metastatic renal cell 
carcinoma; persistent, recurrent, 
or metastatic cervical cancer; 
epithelial ovarian, fallopian 
tube, or primary peritoneal 
cancer; hepatocellular carcinoma
Cetuximab 2004 2004 Competitive inhibition of 
the binding of epidermal 
growth factor
Metastatic colorectal carcinoma
Rituximab 1998 1997 Binding to B-lymphocyte 
antigen CD20 on the surface 





Trastuzumab 2000 1998 Binding to the human 
epidermal growth factor 
2 (HER2) will result 
in inhibition of the 




metastatic gastric or 
gastroesophageal junction 
adenocarcinoma





First monoclonal antibodies used in oncology.
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2. Development of monoclonal antibodies
Monoclonal antibodies consist in homogenous preparations of antibodies – or 
fragments of antibodies – in which every antibody in the product is identical in 
its protein sequence. All antibodies should have the same antigen recognition site, 
affinity, biological interactions, and downstream biological effects [2].
There are four types of monoclonal antibodies [9]:
• Murine: entirely derived from a murine source (hybridoma technology).
• Chimeric: the variable regions are of murine origins whereas the constant 
regions are human.
• Humanized: mostly derived from a human source except for the part of the 
antibody which binds to its target.
• Human: entirely derived from a human source
In summary, the traditional murine hybridoma technique starts by immuniza-
tion of mice with desired antigens to trigger an immune response. Harvested 
splenocytes are fused with myeloma cells to produce hybridoma cells that persis-
tently secrete the antibodies of interest. After the screening, selected leads are used 
to generate chimeric or humanized antibodies [9].
The main concern with this approach is the risk that might result in an immune 
response to the mouse antibody sequence. The consequence of this include allergic 
response and/or reduced bioavailability of mouse monoclonal antibodies. This 
immune response limited their clinical use [10].
Changes in the source of the molecule were determined as a solution to avoid 
the immune response. Introducing engineer changes, for example, recombinant 
DNA technologies, originated the chimeric, humanized, and human antibodies. 
Humanized mice allow for development of monoclonal antibodies with amino 
acid substitutions that lack mouse heavy chains and make them more similar to the 
human sequence system [2, 9].
The first chimeric antibody was approved in 1994 by the United States Food and 
Drug Administration (FDA) for inhibition of platelet aggregation in cardiovascular 
Monoclonal antibody European of Medicines Agencya Food and Drug Administrationb
Trade name Approval date Trade name Approval date
Trastuzumab Ontruzant 2017 Ogivri 2017
Trazimera 2018 Herzuma 2018
Kanjinti 2018 Kanjinti 2019
Ogivri 2018 Ontruzant 2019




*The product received the recommendation of the granting of marketing authorization.
Table 2. 
Biosimilar monoclonal antibodies with marketing approval for cancer treatment (until February 2021).
Biosimilars
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diseases. The drug was developed by combining sequences of the murine vari-
able domain with human constant region domain. In 1997, the first monoclonal 
antibody, rituximab – an immunoglobulin type 1 anti-CD20 -, was approved for 
non-Hodgkin’s lymphoma by the FDA [9]. And the first humanized monoclonal 
antibody approved by the FDA also in 1997 was daclizumab, an anti-IL-2 receptor 
used for the prevention of transplant graft rejection [11].
Human monoclonal antibodies can either be obtained by phage display or 
transgenic animals [9]. Based on these techniques, the first fully human therapeutic 
antibody based on phage display was adalimumab, an anti-tumor necrosis factor 
α human antibody. It was approved in 2002 by the FDA for rheumatoid arthritis. 
Panitumumab, a monoclonal antibodies anti-epidermal growth factor receptor was 
the first human antibody generated in a transgenic mouse, approved by the FDA in 
2006 and indicated for metastatic colorectal carcinoma, a type of cancer [11].
3. Biosimilar monoclonal antibodies in oncology
As mentioned before, three biosimilar monoclonal antibodies are available in 
oncology: bevacizumab, rituximab, and trastuzumab. Cetuximab is in preliminary 
steps of developing a biosimilar.
Bevacizumab is a humanized inhibitor of vascular endothelial growth factor 
(VEGF) monoclonal antibody. It acts by selectively binding circulating VEGF, 
thereby inhibiting the binding of VEGF to its cell surface receptors, which results 
in a reduction of microvascular growth of tumor blood vessels, reducing the blood 
supply to tumor tissues. Other results observed are decrease interstitial pressure on 
tissues, increase vascular permeability, induction of apoptosis of tumor endothelial 
cells, and may increase delivery of chemotherapeutic agents [12].
Rituximab is a chimeric monoclonal antibody that has a high-affinity binding 
to B-lymphocyte antigen CD20 (CD20) on the surface of B cells. The death of B 
cells occurs by different ways, including antibody-dependent cellular cytotoxicity 
(ADCC) and apoptosis [13].
Trastuzumab is a recombinant humanized monoclonal antibody that binds to 
the domain of the extracellular segment of the human epidermal growth factor-2 
receptor (HER2), and inhibits the proliferation and survival of HER2-dependent 
tumors [14]. When trastuzumab is biding to HER2 receptor might occur the 
degradation of the receptor, attraction of immune cells to tumor cells by ADCC and 
inhibition of some pathways involved in the suppression of cell growth and prolif-
eration [15].
4.  Assessment of biological activity of biosimilar monoclonal  
antibodies
The biosimilar needs to demonstrate the proposed product is highly similar to 
the reference biological product and this is determined through a pathway that 
include comparative characterization made by evaluation of physicochemical, 
functional, and clinical characteristics of a biological product [16, 17].
The first step in biosimilar analytic characterization is identifying the char-
acteristics associated with the quality, safety, and efficacy of reference biological 
product. These characteristics are known as critical quality attributes (CQAs) and 
represent physical, chemical, biological, or microbiological property or character-
istic that should be within an appropriate limit, range, or distribution to ensure the 
desired product quality [18].
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Analytic testing of CQAs is performed to detect differences in factors such as 
the expression system, the manufacturing process, physicochemical properties, 
functional activities, receptor binding, immunochemical properties, impurities, 
and clinical outcome of the biosimilar candidate [19, 20].
It may be useful to compare the quality attributes of the proposed biosimilar 
product with those of the reference product using a meaningful fingerprint-like 
analysis. It means the results obtained are extremely sensitive in identifying analyti-
cal differences and allow a very high level of confidence in the analytical similarity 
of the proposed biosimilar product [21].
Once the CQAs for the biosimilar candidate are identified, the next step is to 
categorize the relative importance or criticality of each attribute. In the case of 
monoclonal antibodies, that are more complex biological products, determining 
criticality may be more challenging due to the increased number of attributes to 
evaluate and the potential impact of each difference on the desired product [22].
Significant differences for a very important CQA of the biosimilar candidate, 
such as the primary amino acid structure, are enough to interrupt the biosimilarity 
pathway. The manufacturer will need change their process to reach the high level 
of similarity between this structure in the biosimilar compared with the reference 
product. In the other hand, differences detected among CQAs of very low impor-
tance, such as minor modifications in amino acid side chains, may be acceptable if 
they can be justified or understood as clinically irrelevant [22, 23].
Primary amino acid structure is the core DNA sequence, and it must be exactly 
the same for the biosimilar product and the reference product [22]. There are a range 
of methods commonly used for evaluating the primary structure, including the 
peptide mapping, characterization of disulfide linkages, and glycosylation [24]. If the 
amino acid sequence is not identical, it can happen unwanted amino acid interactions 
that will impact in the safety, efficacy, and immunogenicity of the product [22].
Antibody molecules are molecules consisting of three equalized portions, 
constructed in the same way from paired heavy and light polypeptide chains that 
consists of a series of similar, sequences, each about more than a hundred amino 
acids long [25].
Changes in the protein can occur during any step of the manufacturing process, 
for example, enzymatic modifications, aggregation, variable glycosylation, etc. 
These modifications are named as post translational modifications. They can influ-
ence the physicochemical and biological properties of a protein and affect immuno-
genicity, immune response, and clinical efficacy [26]. In general, proteins can differ 
in at least three ways: (i) primary amino acid sequence; (ii) modification of amino 
acids, such as glycosylation or other side chains; and (iii) higher order structure 
[23]. Glycosylation and phosphorylation can impact on the efficacy and safety of 
a protein, for this reason, during the development process, they are extensively 
tested [22].
When the primary amino acid structure and the three-dimensional structure are 
reached in the biosimilar product, the correct protein arrangement and structural 
integrity are obtained and then, the ability of the biological product to bind to the 
target receptor will result in pharmacologic action. For this reason, target binding is 
considered a very highly CQA [27].
Impurities can be product – or process-related, arising from cell substrates or 
cell culture component [28]. They have the potential to affect all aspects of the 
product’s profile [22]. For this reason, the chosen analytical procedures should be 
adequate to detect, identify, and accurately quantify biologically significant levels 
of impurities [28].
Because the quality attributes of a biosimilar are not identical to those of 
the reference product, in addition to the analytic package, animal toxicology, 
Biosimilars
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pharmacokinetic and pharmacodynamic testing, and immunogenicity studies are 
required by the regulatory agencies for demonstrating biosimilarity [29]. Then, to 
ensure that these differences do not lead to any clinically meaningful differences, 
comparative clinical studies are performed [30]. It is usually necessary to dem-
onstrate comparable clinical efficacy of the biosimilar and the reference product 
in adequately powered, randomized, parallel group comparative clinical trial(s), 
preferably double-blinded and appropriate endpoints chosen [19].
5. Requirements for biosimilar monoclonal antibody clinical trials
Since the first monoclonal antibody have come off patent protection, regula-
tory agencies like European of Medicines Agency (EMA), FDA, Health Canada, 
Australian government Therapeutic Goods Administration (TGA) as well as the 
World Health Organization (WHO), developed guidance to manufactures inter-
ested in submitting applications for biosimilar products approval. Principles for 
designing, conducting, and reporting the results from clinical trials are set by these 
guidelines.
Clinical pharmacology studies are a critical part of demonstrating biosimilarity 
by supporting a demonstration that there are no clinically meaningful differences 
between the proposed biosimilar product and the reference product [21].
The comparison of the pharmacokinetics properties of the biosimilar and 
the reference product forms the first step of a biosimilar monoclonal antibodies’ 
development [29]. It is critical to use the appropriate bioanalytical methods to 
evaluate pharmacokinetics and pharmacodynamics properties [21]. They need to be 
accurate, precise, specific, sensitive, and reproducible.
The design of the study depends on some factors, including clinical context, 
safety, and the pharmacokinetics characteristics of the antibody [29]. Two study 
designs are of particular relevance: single dose crossover designs and parallel study 
designs. For pharmacokinetics similarity assessments, a single dose study, random-
ized, crossover study in healthy volunteers, is generally preferred [21, 29].
Pharmacokinetics and pharmacodynamics studies of trastuzumab (CT-P6 drug) 
[31] and bevacizumab (SB8 drug) [32] were developed with healthy participants. 
On the other hand, rituximab (PF-05280586) [33] were conducted with patients 
(rheumatoid arthritis or lymphoma). A study in healthy subjects is considered to be 
more sensitive in evaluating the product similarity because it is likely to produce less 
pharmacokinetics and/or pharmacodynamics variability compared with a study in 
patients with potential confounding factors [21].
Single dose study is recommended for a product with a short half-life, a rapid 
pharmacodynamics response, and a low anticipated incidence of immunogenicity 
[21]. To biological products with a long half-life, e.g., the mean serum half-life of 
rituximab is 59.8 hours after the first infusion [34], to evaluate clinical pharmacoki-
netics and pharmacodynamics similarity, a parallel group design is more appropri-
ate for this kind of product [21, 29].
To demonstrate comparable clinical efficacy of the biosimilar and the reference 
product, an adequately powered, randomized, parallel group comparative clinical 
trial, preferably double-blind, by using efficacy endpoints is usually necessary [19].
Confirmatory trials (superiority trials) for new drugs should demonstrate that 
the investigational product provides clinical benefit. In this way, FDA and EMA 
have published guidance to applicants, providing background information and 
general regulatory principles for cancer clinical trials [7, 35]. Acceptable primary 
clinical endpoints in this kind of trial include cure rate, overall survival (OS), 
progression free survival (PFS), disease free survival (DFS) [7, 35].
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While clinical trials of originator products aim to demonstrate patient benefit, in 
the biosimilar comparable studies the intention is to compare the biosimilar product 
with the reference product to exclude clinically relevant product-specific differ-
ences [36]. In this case, the most appropriate study design is the equivalence study, 
and in some specific cases, non-inferiority trial may be accepted after to discuss 
with regulatory authorities [19, 23, 29]. For this, the manufacturer needs justify on 
the basis of a strong scientific rationale.
OS is considered the most reliable cancer endpoint because is precise, easy to 
measure and the bias is not a factor to worried. It is defined as the time from ran-
domization until death from any cause. It is measured in the intent-to-treat popula-
tion [29, 35]. As it is necessary to perform the study with long follow-up periods 
in large trials, this endpoint is not usually expected to be present in the biosimilar 
studies and it is not required by the regulatory agencies.
In the comparable studies, it is not necessary to use the same primary efficacy 
endpoints as those that were used in the marketing authorization application of the 
reference product [19, 37]. However, EMA advises to include some common end-
points to facilitate comparisons to the clinical trials conducted with the reference 
product [19].
At moment, a large number of studies with bevacizumab, rituximab and trastu-
zumab biosimilar are using the ORR as the primary endpoint, and EFS, PFS as the 
secondary endpoint (Table 3). OS is less frequently used.
ORR is defined by the regulatory agencies as the proportion of patients with 
tumor size reduction of a predefined amount and for a minimum time period. The 
FDA has defined ORR as the sum of partial responses plus complete responses (CRs) 
[35]. ORR is a direct measure of a drug antitumor activity and should be assessed 
using a standardized criterion to determine the response [35]. The most common is 
the Response Evaluation Criteria in Solid Tumors (RECIST) guideline [55].
Beyond the pharmacokinetics and pharmacodynamics analyses, and clinical 
results, immunogenicity data should be collected and evaluated too. The goal is 
to investigate presence of an immune response to the therapeutic protein and its 
clinical impact [56].
The risk of immunogenicity varies between products and product categories, as 
well, between individuals and patient groups [56]. The consequences of an immune 
reaction to a therapeutic protein range from transient presence of anti-drug anti-
body (ADA) without any clinical significance to severe life-threatening conditions 
[56]. Immune responses to therapeutic protein products have the potential to affect 
product pharmacokinetic, pharmacodynamics, safety, and efficacy [56, 57].
When an ADA binds to or near the active site of a therapeutic protein or induces 
conformational changes, binding to relevant receptors will not happen and it 
will affect efficacy of the product. Besides these conformational-based effects, in 
addition immune-based adverse effects can happen. This includes injection-site and 
infusion reactions [56].
Among the product-related factors we have the protein origin (e.g. human or 
animal) and nature of the active substance (endogenous protein, post-translational 
modifications), significant modifications in the molecule structure, process-related 
impurities, formulation (excipients) and the interactions between the drug and/or 
formulation with the primary product packaging [56].
Immunogenicity testing of the biosimilar and the reference product should be 
conducted within the biosimilar comparability exercise by using the same assay 
format and sampling schedule which must meet all current standards [56, 58]. 
Assays used to detect antibodies against monoclonal antibody are often more 








Trade name Study name or ID Study design Population and sample size (N) Primary endpoint
Bevacizumab Mvasi [38] 20120265 Non-inferiority study, randomized, double-blind, 
parallel, randomized
unresectable, locally advanced, or 
metastatic non-small cell lung cancer 
(642)
ORR
Zirabev [39] B7391003 Equivalence study, double-blind, parallel, 
randomized
unresectable, locally advanced, recurrent 
or metastatic non-squamous non-small 
cell lung cancer (719)
ORR
Equidacent [40] FKB238-002 Equivalence study, double-blind, parallel, 
randomized
Newly diagnosed advanced (stage IV) /
recurrent NS-NSCLC (731)
ORR
Aybintio [41] SB8-G31-NSCLC Equivalence study, double-blind, parallel, 
randomized
Metastatic or recurrent nonsquamous 
Non-small Cell Lung Cancer (763)
ORR
Onbevzi No information for public access
Alymsys
Oyavas
Rituximab Riabni [42] 20130109 equivalence study, randomized, double-blind, 
parallel
low tumor-burden follicular lymphoma 
(256)
ORR
Ruxience [43] REFLECTIONS 
B328-06
equivalence study, randomized, double-blind, 
parallel
low tumor burden follicular lymphoma 
(394)
ORR
Truxima [44] CT-P10 3.3 non-inferiority, randomized, double-Blind, parallel Advanced Follicular Lymphoma (121) ORR
Riximyo [45] GP13-301 Equivalence study, randomized, double-blind, 
parallel
previously untreated, advanced stage 
follicular lymphoma (629)
ORR
Blitzima [46] CT-P10 3.3 non-inferiority, randomized, double-blind, parallel Advanced Follicular Lymphoma (121) ORR
Rixathon [47] GP13-301 Equivalence study, randomized, double-blind, 
parallel

































Trade name Study name or ID Study design Population and sample size (N) Primary endpoint
Trastuzumab Ogivri [49] MYL-Her-3001 equivalence study, randomized, double-blinded, 
parallel
metastatic breast cancer (458) ORR
Trazimera [50] B3271002 equivalence study, randomized, double-blind, 
parallel
metastatic breast cancer (707) ORR
B3271004 non-inferiority study, randomized, double-blind, 
parallel
operable breast cancer (226) pCR
Kanjinti [51] 20120283 equivalence study, randomized, double-blind, 
parallel
operable breast cancer (725) pCR
Ontruzant [52] SB3-G31-BC equivalence study, randomized, double-blinded, 
parallel
operable breast cancer (875) pCR
Herzuma [53] CT-P6 3.2 equivalence study, randomized, double-blind, 
parallel
operable breast cancer (549) pCR
Zercepac [54] HLX02-BC01 equivalence study, randomized, double-blind, 
parallel
metastatic breast cancer (649) ORR
Legend: ORR, overall response rate; pCR, pathological complete response.
Table 3. 
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Finally, when all tests are done and the authorization holder will submit the docu-
ments to receive the marketing authorization, it can be extrapolating all indications 
from the reference product to the biosimilar. When biosimilar comparability has 
been demonstrated in one indication, extrapolation of clinical data to other indica-
tions of the reference product could be acceptable but needs to be scientifically justi-
fied. It is expected that the safety and efficacy can be extrapolated when biosimilar 
comparability has been demonstrated in all aspects described before [19, 23, 29].
This condition is not applied in all situations. For example, if a reference mono-
clonal antibody is licensed both as an immunomodulator and as an anticancer anti-
body, the scientific justification as regards extrapolation between the two indication 
is more challenging and may have to involve more specific studies [29].
6. Conclusions
Since monoclonal antibodies play an essential role in cancer treatment and are 
responsible for high healthcare costs, the development of biosimilars is particularly 
important in oncology. Several biosimilars of the monoclonal antibodies trastu-
zumab, rituximab, and bevacizumab have been approved and began to be marketed 
in Europe, EUA and other countries around the world. More diversification of 
monoclonal antibodies biosimilars is expected in the next years, as the patent of 
other molecules will expire.
The biosimilar development pathway consists of a comprehensive comparabil-
ity exercise between the biosimilar candidate and the reference product, primarily 
focusing on data from analytical studies. Clinical studies for biosimilar candidates 
follow a different design to those for a new biological. Adequate information on 
the biosimilar approval pathway, the robustness of overall evidence used to dem-
onstrate biosimilarity, and how the clinical development of a biosimilar is done is 
important for all: professional, patient, governments, and other stakeholders.
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